Sector News

As Amazon entry into pharma looms, CEOs see plenty of room for change in distribution

November 2, 2017
Life sciences

Online retailing giant Amazon has yet to publicly disclose any plans to get into drug sales, but the mere speculation has pharma CEOs thinking, and speaking, about how it could entirely remake their world.

Pfizer CEO Ian Read Tuesday told analysts “any system of distribution that can cut costs and get a wide availability of products to patients is something that the whole industry would be interested in.” But he added that it’s “somewhat more of a difficult strategic proposal” if the tech giant tries getting into the pharmacy benefit manager industry, as that’s a “whole different skill set.”

Addressing the current drug distribution landscape, Allergan CEO Brent Saunders said he believes the “whole ecosystem is ripe for disruption.” But he stressed the changes should be associated with “improvements based on technology or efficiency,” such as the way new treatments are reshaping care for patients.

Analysts and industry watchers have been talking about Amazon’s options in pharmaceuticals for several months, presenting a number of scenarios about moves it might make. CNBC has reported that the company plans to make its decision whether to enter the pharma space by Thanksgiving.

Speculation about Amazon becoming a drug retailer ratcheted up last week after the St. Louis Post-Dispatch reported that it has secured wholesale pharmacy licenses in multiple states. Speaking with CNBC, one expert cautioned that the news doesn’t necessarily mean the company plans an entry into the drug space, rather that it needs the licenses for its existing medical businesses.

Amazon has remained publicly noncommittal. Questioned on the topic during Amazon’s earnings call, the company’s chief financial officer said he couldn’t “confirm or deny any of the rumors related to pharmacy or anything else.”

However, Wells Fargo analyst David Maris noted that AmazonRx.com is licensed to the Amazon Legal Department. The analyst and his team wrote that Amazon’s entry into the drug business would be a “negative headwind for branded retail pharmaceuticals, retail generics and OTC products.”

“We find it easy to envision that, if it entered pharmacy, Amazon could offer unique value to some customers, such as the easier ability to manage prescriptions and perhaps discounts, such as free generics to Prime users,” the analyst wrote.

On GlaxoSmithKline’s third-quarter call, Maris noted, executives explained that the company’s OTC business is seeing pricing pressure from traditional retailers who are trying to compete for business against online players. They’re going to the manufacturer to try and get better pricing, he said.

Goldman Sachs analysts have put out a 30-page report outlining several options for Amazon in pharmaceuticals, writing that a partnership with an existing PBM is a “path of least resistance.” One Bernstein analyst said he believes the company will have its pharmacy business set up by 2019 and ready to compete for business in 2020, while a Leerink analyst has said “it’s a matter of when, not if” that Amazon will move into drugs.

For his part, Maris wrote that “even though Amazon has not stated a goal to be in pharmacy, history has shown it is better to consider Amazon’s disruptive potential beforehand rather than afterward.”

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).